AR037771A1 - Moleculas pequenas para el tratamiento del crecimiento celular anormal - Google Patents
Moleculas pequenas para el tratamiento del crecimiento celular anormalInfo
- Publication number
- AR037771A1 AR037771A1 ARP020104778A ARP020104778A AR037771A1 AR 037771 A1 AR037771 A1 AR 037771A1 AR P020104778 A ARP020104778 A AR P020104778A AR P020104778 A ARP020104778 A AR P020104778A AR 037771 A1 AR037771 A1 AR 037771A1
- Authority
- AR
- Argentina
- Prior art keywords
- small molecules
- treatment
- cell growth
- abnormal cell
- erbb2
- Prior art date
Links
- 150000003384 small molecules Chemical class 0.000 title abstract 4
- 230000002159 abnormal effect Effects 0.000 title abstract 3
- 230000010261 cell growth Effects 0.000 title abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 108060006698 EGF receptor Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Moléculas pequenas que son útiles en el tratamiento del crecimiento celular anormal, tal como el cáncer, en mamíferos. Procedimiento de uso de tales moléculas pequenas en el tratamiento del crecimiento celular anormal en mamíferos, especialmente en seres humanos, y a composiciones farmacéuticas que contienen tales compuestos. Pequenas moléculas que son selectivas para el receptor erbB2 respecto al receptor erbB1, teniendo dicho inhibidor de erbB2 un intervalo de selectividades por erbB2 respecto a erbB1 entre 50-1500.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34109101P | 2001-12-12 | 2001-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037771A1 true AR037771A1 (es) | 2004-12-01 |
Family
ID=23336198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020104778A AR037771A1 (es) | 2001-12-12 | 2002-12-10 | Moleculas pequenas para el tratamiento del crecimiento celular anormal |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US20030171386A1 (es) |
| EP (1) | EP1465632A1 (es) |
| JP (1) | JP4181502B2 (es) |
| KR (1) | KR20040063948A (es) |
| CN (1) | CN1602195A (es) |
| AP (1) | AP2004003058A0 (es) |
| AR (1) | AR037771A1 (es) |
| AU (1) | AU2002339687A1 (es) |
| BR (1) | BR0214499A (es) |
| CA (1) | CA2469670A1 (es) |
| DO (1) | DOP2002000545A (es) |
| EA (1) | EA200400680A1 (es) |
| EC (1) | ECSP045146A (es) |
| GT (1) | GT200200273A (es) |
| HR (1) | HRP20040529A2 (es) |
| HU (1) | HUP0501069A2 (es) |
| IL (1) | IL161908A0 (es) |
| IS (1) | IS7233A (es) |
| MA (1) | MA27154A1 (es) |
| MX (1) | MXPA04004107A (es) |
| NO (1) | NO20042882L (es) |
| OA (1) | OA12734A (es) |
| PA (1) | PA8561301A1 (es) |
| PE (1) | PE20030760A1 (es) |
| PL (1) | PL373848A1 (es) |
| TN (1) | TNSN04111A1 (es) |
| TW (1) | TW200301121A (es) |
| WO (1) | WO2003049740A1 (es) |
| ZA (1) | ZA200404264B (es) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| EP1521747B1 (en) * | 2002-07-15 | 2018-09-05 | Symphony Evolution, Inc. | Receptor-type kinase modulators and methods of use |
| RU2005119172A (ru) * | 2002-12-18 | 2006-01-20 | Пфайзер Продактс Инк. (Us) | Производные 4-анилинхиназолина для лечения патологического роста клеток |
| RU2005122659A (ru) * | 2002-12-19 | 2006-01-20 | Пфайзер Продактс Инк. (Us) | Комплексы е-2-метокси-n-(3-{4-[3-метил-4-(6-метилпиридин-3-илокси) фениламино] хиназолин-6-ил} аллил) ацетамида, способ получения и применения указанных комплексов |
| KR20060037447A (ko) * | 2003-08-18 | 2006-05-03 | 화이자 프로덕츠 인크. | ｅｒｂＢ２ 항암제에 대한 투약 스케쥴 |
| MXPA06002964A (es) | 2003-09-16 | 2006-06-14 | Astrazeneca Ab | Derivados de quinazolina como inhibidores de cinasa de tirosina. |
| ES2925655T3 (es) * | 2003-09-26 | 2022-10-19 | Exelixis Inc | Moduladores c-Met y métodos de uso |
| GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| CN1921864A (zh) * | 2003-12-24 | 2007-02-28 | 西奥斯公司 | 使用TGF－β抑制剂治疗神经胶质瘤 |
| EP1713781B1 (en) | 2004-02-03 | 2008-11-05 | AstraZeneca AB | Quinazoline derivatives |
| AP2204A (en) * | 2004-05-06 | 2011-02-07 | Warner Lambert Co | 4-phenylamino-quinazolin-6-yl-amides. |
| GB0417107D0 (en) * | 2004-07-30 | 2004-09-01 | Wellcome Trust The | Genes II |
| EP1896451A2 (en) * | 2005-06-03 | 2008-03-12 | Pfizer Products Incorporated | Bicyclic derivatives for the treatment of abnormal cell growth |
| EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
| CA2673097A1 (en) | 2006-12-12 | 2008-06-19 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| EP2118075A1 (de) | 2007-02-06 | 2009-11-18 | Boehringer Ingelheim International GmbH | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| CN101939316B (zh) | 2008-02-07 | 2013-10-02 | 贝林格尔.英格海姆国际有限公司 | 螺环杂环化合物、含有所述化合物的药物、其用途及其制备方法 |
| TW200944528A (en) | 2008-03-12 | 2009-11-01 | Takeda Pharmaceutical | Fused heterocyclic compound |
| BRPI0912170A2 (pt) | 2008-05-13 | 2015-10-13 | Astrazeneca Ab | composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente |
| US8648191B2 (en) | 2008-08-08 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
| KR20250123237A (ko) | 2009-01-16 | 2025-08-14 | 엑셀리시스, 인코포레이티드 | 암의 치료를 위한 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형 |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| WO2011153050A1 (en) | 2010-06-02 | 2011-12-08 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to her2/neu receptor complex |
| US8993634B2 (en) | 2010-06-02 | 2015-03-31 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to Her2/neu receptor complex |
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| BR112014004762A2 (pt) | 2011-08-31 | 2018-06-19 | Genentech Inc | métodos de determinação da sensibilidade de crescimento de célula tumoral á inibição por um inibidor de quinase de egfr, de identificação de um paciente com câncer que provavelmente irá se beneficiar do tratamento com um inibidor de efgr, de tratamento de um câncer em um paciente, de seleção de uma terapia para um paciente com câncer e de determinação de superexpressão de gene erbb2 em uma célula |
| US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
| KR101589632B1 (ko) | 2014-06-03 | 2016-02-01 | 한국과학기술연구원 | 항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체 |
| CN111643479B (zh) | 2015-07-01 | 2023-10-27 | 加州理工学院 | 基于阳离子粘酸聚合物的递送系统 |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| WO2019241327A1 (en) | 2018-06-13 | 2019-12-19 | California Institute Of Technology | Nanoparticles for crossing the blood brain barrier and methods of treatment using the same |
| US20230126204A1 (en) | 2020-02-03 | 2023-04-27 | Boehringer Ingelheim International Gmbh | [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS |
| US20230131720A1 (en) * | 2020-02-03 | 2023-04-27 | Boehringer Ingelheim International Gmbh | [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS |
| CN113429390B (zh) * | 2020-03-23 | 2022-04-15 | 苏州恩华生物医药科技有限公司 | 喹唑啉衍生物及其应用 |
| US11608343B2 (en) | 2020-04-24 | 2023-03-21 | Boehringer Ingelheim International Gmbh | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US5654307A (en) * | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| ZA986729B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| JP3270834B2 (ja) * | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
| UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| JP2003504363A (ja) * | 1999-07-09 | 2003-02-04 | グラクソ グループ リミテッド | プロテインチロシンキナーゼ阻害剤としてのアニリノキナゾリン類 |
| DE60017179T2 (de) * | 1999-10-19 | 2006-01-05 | Merck & Co., Inc. | Tyrosin kinaseinhibitoren |
| JP4044839B2 (ja) * | 2000-06-22 | 2008-02-06 | ファイザー・プロダクツ・インク | 異常細胞増殖を治療するための置換２環式誘導体 |
| WO2003050108A1 (en) * | 2001-12-12 | 2003-06-19 | Pfizer Products Inc. | Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer |
-
2002
- 2002-11-04 HR HR20040529A patent/HRP20040529A2/hr not_active Application Discontinuation
- 2002-11-04 AU AU2002339687A patent/AU2002339687A1/en not_active Abandoned
- 2002-11-04 JP JP2003550789A patent/JP4181502B2/ja not_active Expired - Fee Related
- 2002-11-04 CA CA002469670A patent/CA2469670A1/en not_active Abandoned
- 2002-11-04 EA EA200400680A patent/EA200400680A1/ru unknown
- 2002-11-04 CN CNA028237293A patent/CN1602195A/zh active Pending
- 2002-11-04 BR BR0214499-9A patent/BR0214499A/pt not_active IP Right Cessation
- 2002-11-04 PL PL02373848A patent/PL373848A1/xx not_active Application Discontinuation
- 2002-11-04 IL IL16190802A patent/IL161908A0/xx unknown
- 2002-11-04 MX MXPA04004107A patent/MXPA04004107A/es not_active Application Discontinuation
- 2002-11-04 KR KR10-2004-7009022A patent/KR20040063948A/ko not_active Ceased
- 2002-11-04 OA OA1200400160A patent/OA12734A/en unknown
- 2002-11-04 EP EP02777736A patent/EP1465632A1/en not_active Withdrawn
- 2002-11-04 AP APAP/P/2004/003058A patent/AP2004003058A0/en unknown
- 2002-11-04 WO PCT/IB2002/004636 patent/WO2003049740A1/en not_active Ceased
- 2002-11-04 HU HU0501069A patent/HUP0501069A2/hu unknown
- 2002-12-10 TW TW091135662A patent/TW200301121A/zh unknown
- 2002-12-10 PE PE2002001190A patent/PE20030760A1/es not_active Application Discontinuation
- 2002-12-10 US US10/315,863 patent/US20030171386A1/en not_active Abandoned
- 2002-12-10 AR ARP020104778A patent/AR037771A1/es unknown
- 2002-12-10 DO DO2002000545A patent/DOP2002000545A/es unknown
- 2002-12-12 GT GT200200273A patent/GT200200273A/es unknown
- 2002-12-12 PA PA20028561301A patent/PA8561301A1/es unknown
-
2004
- 2004-04-26 IS IS7233A patent/IS7233A/is unknown
- 2004-05-31 ZA ZA200404264A patent/ZA200404264B/en unknown
- 2004-06-08 MA MA27731A patent/MA27154A1/fr unknown
- 2004-06-10 EC EC2004005146A patent/ECSP045146A/es unknown
- 2004-06-11 TN TNP2004000111A patent/TNSN04111A1/fr unknown
- 2004-07-07 NO NO20042882A patent/NO20042882L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP4181502B2 (ja) | 2008-11-19 |
| PL373848A1 (en) | 2005-09-19 |
| WO2003049740A1 (en) | 2003-06-19 |
| US20030171386A1 (en) | 2003-09-11 |
| ZA200404264B (en) | 2005-08-31 |
| CA2469670A1 (en) | 2003-06-19 |
| KR20040063948A (ko) | 2004-07-14 |
| MXPA04004107A (es) | 2004-07-23 |
| PA8561301A1 (es) | 2003-12-30 |
| IL161908A0 (en) | 2005-11-20 |
| TW200301121A (en) | 2003-07-01 |
| TNSN04111A1 (fr) | 2006-06-01 |
| CN1602195A (zh) | 2005-03-30 |
| AU2002339687A1 (en) | 2003-06-23 |
| AP2004003058A0 (en) | 2004-06-30 |
| HUP0501069A2 (en) | 2006-06-28 |
| MA27154A1 (fr) | 2005-01-03 |
| EA200400680A1 (ru) | 2005-06-30 |
| HRP20040529A2 (en) | 2004-10-31 |
| ECSP045146A (es) | 2004-07-23 |
| PE20030760A1 (es) | 2003-09-05 |
| OA12734A (en) | 2006-06-28 |
| BR0214499A (pt) | 2005-05-10 |
| JP2005527486A (ja) | 2005-09-15 |
| DOP2002000545A (es) | 2003-06-16 |
| NO20042882L (no) | 2004-07-07 |
| GT200200273A (es) | 2003-10-03 |
| EP1465632A1 (en) | 2004-10-13 |
| IS7233A (is) | 2004-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR037771A1 (es) | Moleculas pequenas para el tratamiento del crecimiento celular anormal | |
| PA8468401A1 (es) | Compuestos para el tratamiento de la isquemia | |
| PA8680701A1 (es) | Derivados de oxindol | |
| ECSP055582A (es) | Derivados de benzotiazol que tienen actividad agonista de beta-2-adrenorreceptor | |
| ECSP066406A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| ECSP045407A (es) | Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf | |
| AR050616A1 (es) | Composiciones farmaceuticas para el tratamiento de trastornos hiperproliferativos. | |
| ECSP003682A (es) | Compuestos para el tratamiento de la isquemia | |
| PA8643201A1 (es) | Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa | |
| AR031975A1 (es) | Compuestos analogos de (1r,cis)-4-(6-amino-9h-purin-9-il) -2-ciclopenteno-1-metanol, proceso para su preparacion, su uso en el tratamiento de infecciones virales, y envase que los contiene | |
| UY27732A1 (es) | Uso de análogos del benzimidazol en el tratamiento de la proliferación celular. | |
| BRPI0514474A (pt) | multiparticulados | |
| NI200800060A (es) | Bencimidazoles sustituidos como inhibidores de cinasa. | |
| ECSP941111A (es) | Nuevas sulfonilaminopirimidinas, | |
| GT200600517A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| AR049915A1 (es) | Compuestos con contenido de boro y metodos de uso de los mismos | |
| UY27894A1 (es) | Derivados de cinamida. | |
| ECSP045219A (es) | Derivados de quinazolinona y su uso como agonistas cb | |
| UY27452A1 (es) | Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer | |
| UY28731A1 (es) | Compuestos quimicos | |
| PA8618401A1 (es) | Prevencion y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1.3,5(10)-trien-3,16alfa-diol | |
| AR072426A1 (es) | Uso de nifurtimox para el tratamiento de enfermedades causadas por tricomonadida | |
| UY29109A1 (es) | Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios | |
| UY27576A1 (es) | Moléculas pequenas para el tratamiento del crecimiento celular anormal | |
| UY27394A1 (es) | Pedidos con actividad anti- angiogéna. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |